Lexaria Biosciences
Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and many more patents pending worldwide. Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery.
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Kelowna, BC / ACCESS Newswire / December 15, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,661,600…
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Kelowna, BC / ACCESS Newswire / September 26, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667…
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
April 25, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2,000,000 shares of…
Lexaria Bioscience Corp. Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria entered into a definitive agreement for a registered direct offering of 1,633,987 shares of common stock at $3.06 per share, with concurrent unregistered warrants. Gross proceeds are expected to be approximately $5 million.
Lexaria Releases Strategic Letter from the Outgoing CEO
September 5, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer (“CEO”) Chris Bunka as a strategic update to all stakeholders. CEO LETTER TO…
Positive Interim Body Weight Results from Lexaria’s Diabetes Animal Study
liraglutide · DehydraTECH appears to be working with semaglutide both with and without SNAC technology · DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 · Dosing in the final four study arms has now begun Kelowna, British Columbia – July 17, 2024 – Lexaria Bioscience Corp.…
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents…
Lexaria Bioscience CEO Letter to Stakeholders
Lexaria's CEO reflects on a difficult 2023 for microcap companies and lays out the Company's plans and outlook for 2024.
Official press releases sourced from public company filings. Links open the original release.